Biosimilars Market Research Reports & Industry Analysis

Biosimilars (otherwise termed follow-on-biologics, or FOBs for short) stand for the versions of biopharmaceuticals, which have the resembling but not identical parent molecule, and are created either by living organisms or from living micro-organisms by way of rDNA (recombinant DNA) or supervised gene expression technologies. The approval of Biosimilars occurs via strictly defined regulatory paths based on whether FOBs have shown comparability with their reference substance.

The worldwide Biosimilars Market is anticipated to surpass a EUR 14.9bn mark by end 2018. The major drivers encompass cost efficiency of biosimilars versus their high-priced analogues, the enlarging thirst for biotechnology drugs, imminent biotech drugs’ patent expiries, the planet’s aging population, and the rising frequency of critical illnesses. The illustrious actors on the global Biosimilars stage encompass Biocon, Intas Biopharmaceuticals, Cipla, Biopartners, Hospira, Wockhardt, Teva Pharmaceutical Industries, Sandoz International, amidst others.

The Catalogue’s research reports offer world, region and nation-wise analyses of the Biosimilars Market development over various time periods. The researches are lavish with discussions of the Biosimilars Industry growth rate, structure and capacity. The market trends, growth obstacles/stimulators, key products and those in R&D stage, and more issues are studied in the reports. Additionally, the research reports indicate and profile the leading players and hoped-for entrants, and offer market projections and forecasts.

Found 91 publications
Global Biosimilars Industry Report 2015 US$ 2,800.00

The Global Biosimilars Industry Report 2015 is a professional and in-depth study on the current state of the Biosimilars industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Biosimilars market ...

Jul, 2015 176 pages
The Future of Biosimilars 2015 US$ 2,100.00

... the future of the biosimilars market A Report for the Entire Industry The biosimilars market is evolving quickly, making Future of Biosimilars 2015 a must-read reference not only for those working in biosimilars competitive intelligence ...

Jun, 2015 120 pages
Physician Views: Will Patient Switching Studies Support Biosimilar Adoption? US$ 695.00

... market will at some point provide a secondary benchmark for biosimilar developers, physicians, patients and payers, when data from a much anticipated 500-patient switching study ... in the EU5 the following questions this week… Has your view towards current/future usage of biosimilar TNF inhibitors become more ...

Jun, 2015
BIOSIMILARS - Regulatory Framework and Pipeline Analysis US$ 2,995.00

BIOSIMILARS - Regulatory Framework and Pipeline Analysis Summary Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are ... dynamics: Trends, Drivers, and Barriers WHO guidance for biosimilars Regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for: Europe, USA, India ...

Jun, 2015 94 pages
Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars US$ 750.00

... latest Chinese guidance for development, evaluation, license approval of biosimilars, Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars provided a comprehensive and thorough knowledge of the latest Chinese guidance for development, evaluation, license approval of biosimilars ...

May, 2015 48 pages
Evolution of Technologies for Therapeutic Antibodies-From mAbs to Biosimilars US$ 1,999.00

The report provides in-depth information on technologicial platforms being developed for monoclonal antibodies and how they have been improvised for biosimilar development. Also various issues pertaining to manufacturing of biosimilars have been highlighted with possible solutions to to address the hurdles.

Jan, 2015 64 pages
Physician Views: Oncologists React to Approval of Zarxio – the First US Biosimilar US$ 695.00

... for. FirstWord polled US-based oncologists on this issue, among others, following the ODAC meeting in January (see Physician Views Poll Results: Positive FDA sentiment for biosimilar Neupogen shared by oncologists). While Zarxio is a trailblazer in the ...

Mar, 2015
Physician Views: CMS Guidance on Biosimilar Reimbursement – What Do Oncologists and Rheumatologists Think? US$ 695.00

... physician sentiment to the CMS guidance. In our first poll, focused on Part B reimbursement, we are asking oncologists… How effective they expect the CMS reimbursement guidance to be in incentivising physicians ... of 'de-facto' interchangeability via CMS guidance Their view on interchangeability status for ...

Apr, 2015
Biosimilars: US Payer Perspectives US$ 2,100.00

... from some leading investment banks claiming that biosimilars in the US are on the cusp of greatness. Biosimilars: US Payer Perspectives provides a much needed tonic to perhaps the overly optimistic sentiment that has seeped into the discussions about the US biosimilars opportunity ...

Apr, 2015
Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors US$ 1,500.00

Competitor Analysis: The rapeutic Antibodies 2015: Biosimilars & Biosuperiors This Competitive Intelligence Report about The rapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor ...

Apr, 2015 414 pages
Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders US$ 6,900.00

... , Spain and Italy, Medical Affairs Reputations (EU5): Biosimilar mAbs in Inflammatory Disorders offers insights on how Medical Affairs teams from companies developing and marketing biosimilar anti-TNF monoclonal ... , Spain, the UK; EU5 – biosimilar mAb developers and companies marketing branded mAbs require solid evidence upon which to base medical affairs’ strategy for their ...

Feb, 2015
Biosimilars: European Payer Perspectives US$ 1,950.00

... when it comes to European biosimilars. One issue unites European healthcare payers: the need to provide biosimilars at the most affordable price in cash constrained health services. Biosimilars: European Payer Perspectives is a thought ... healthcare payers: the need to provide these products at the most affordable price in cash constrained health services. Biosimilars: European Payer Perspectives gives payer insights on how healthcare payers ...

Jan, 2015
Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 US$ 3,495.00

Biosimilars (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 SUMMARY Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the ... Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Biosimilars including ...

Dec, 2014 82 pages
2015 Deep Research Report on Global Biologics and Biosimilars Industry US$ 2,600.00

2015 Deep Research Report on Global Biologics and Biosimilars Industry is a professional and ... analysis, investment return analysis, and development trend analysis. In conclusion, it is a deep research report on Global Biologics and Biosimilars industry. Here, we express ...

Feb, 2015 170 pages
Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin US$ 390.00

Competitor Analysis: Her2 Antibodies 2015 - Biosimilars and Biosuperiors of Herceptin This Competitive Intelligence Report about Her2 Antibodies 2015 - Biosimilars and ... and make out about 81% of the franchise sale. Therefore, the Her2 antibody market is not only highly attractive for biosimilar developments ...

Feb, 2015 64 pages
Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis US$ 460.00

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis This Competitive Intelligence Report about VEGF and VEGF-R ... more cancer and eye disease indications. The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground ...

Feb, 2015 79 pages
Global Biosimilar Market Trends & Opportunities: 2015 Edition US$ 800.00

... trials are increasing at a rate of 20% annually. The report titled “The Global Biosimilar Market: Trends & Opportunities (2014-2018)” provides an in-depth analysis of the ... and will be driving the growth of the industry. Growth of the overall Biosimilars industry has also been forecasted for the period 2014 ...

Jan, 2015 80 pages
New Phase of Mab biosimilar knocks the door Biosimilar Oppurtunities In Japan US$ 4,000.00

... Japan biosimilar market. Consolidation activities are in place for biosimilar entry by a couple of big players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei ...

Jan, 2015 65 pages
Physician Views: What opportunity for biosimilar basal insulin? US$ 695.00

... have historically had minimal opportunity to leverage discounts from an oligopolistic ... well established players, it remains to be seen how comfortable physicians would be using a 'biosimilar' insulin developed by ... as 'interchangeable' with branded Lantus). Similarly, what percentage of patients would you be ...

Nov, 2014
Physician Views: Biosimilar Lucentis – what opportunity? US$ 695.00

... Lucentis, while the availability of compounded Avastin, used as an alternative to Lucentis at a much cheaper cost, adds further confusion to the market outlook. Furthermore, a Physician Views ... therapies persists). FirstWord's Biosimilar Index reveals just one biosimilar Lucentis product in development; PF582 ...

Oct, 2014
Europe Biosimilars Market & Pipeline Insight US$ 2,400.00

... (epoetin zeta), Silapo (epoetin zeta), Tevagrastim (filgrastim), Zarzio (filgrastim), Wepox (epoetin alfa) “Europe Biosimilars Market & Pipeline Insight” Report Highlight: Biosimilars Market Overview & Trend Analysis by Country Biosimilars Introduction Timeline in Europe Biosimilars Development & ...

Oct, 2014 360 pages
Biosimilars - Biosimilars on the Cusp of a New Era US$ 2,995.00

... and launches of new biosimilar products The position of HTA and P&R agencies on biosimilars Industry perspective on the expected impact of biosimilars The biosimilars pipeline and key future developments Key companies involved in biosimilars The way ...

Jul, 2014 58 pages
Global Biosimilars Market Regulations & Pipeline Insight US$ 2,400.00

... , the monoclonal antibodies (mAbs) and insulin market would witness maximum growth, with these two segments accounting for a dominant share ... drugs losing their patents by 2020. “Global Biosimilars Market Regulations & Pipeline Insight” Report Highlights: Market Overview Detailed Regulatory Pathways For ...

Sep, 2014 836 pages
Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis,... US$ 4,515.00

... DELIVERABLES Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography. MARKET BY TECHNOLOGY Monoclonal Antibodies (MAb) Technology Recombinant DNA Technology (rDNA technology) Nuclear magnetic resonance (NMR) technology ...

Jul, 2014 184 pages
PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market US$ 2,995.00

PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market SUMMARY GlobalData’s report, 'PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market', provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements ...

Jun, 2014 173 pages
Physician Views: New FDA biosimilar guidance – an initial reaction from oncologists and rheumatologists US$ 695.00

... , the FDA published new guidance on the requirements for developing biosimilars for the US market – specifically focused on clinical pharmacology requirements ... , but potentially how they are used by physicians. In light of the FDA's new guidance, FirstWord is polling US-based oncologists and rheumatologists ...

May, 2014
The Future of Biosimilars: mapping critical uncertainties and the impact of future events US$ 1,950.00

... , to legal challenges and questions about its profitability, The Future of Biosimilars: Mapping Critical Uncertainties and the Impact of Future Events provides ... and most up-to-date access to recent and future events in the biosimilars market, including battles being waged over policy, regulatory, intellectual ...

May, 2014 125 pages
Physician Views – Are physicians getting the biosimilar education they need? US$ 695.00

... are physicians ready for biosimilars and is the industry doing enough to educate who is arguably the key stakeholder in this market? As physician ... for biosimilar developers and Physician Views: At least some similarity needed in biosimilar naming conventions, say majority of physicians, but caveats remain In a ...

Apr, 2014
Biosimilar Index: Tracking the Global Biosimilar Pipeline US$ 5,295.00

... is not, significant. That is where the Biosimilar Index comes in. A new force in biosimilar and NCB drug and market tracking FirstView’s Biosimilar Index is a new, comprehensive drug intelligence ... both on-going tracking of development and interpretation of the commercial and clinical significance. Two class beating services in one subscription! Biosimilar Index: Pipeline Database ...

Apr, 2014
Physician Views: Biosimilar naming conventions – what do physicians think? US$ 695.00

... what do physicians think? What do they consider to be the correct naming convention and how will this impact their potential usage of biosimilars. This week's Physician Views poll will ask US and EU5-based oncologists and rheumatologists: What naming convention for biosimilar products they believe ...

Feb, 2014
Global EPO Biosimilars Market Outlook 2018 US$ 400.00

... governments and private players worldwide stepping into this industry, the market shows bright prospects and immense opportunities to cash in on. As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global EPO biosimilars market will grow at a CAGR of around 37% ...

Feb, 2014 45 pages
Global Biosimilar Market Outlook 2020 US$ 1,500.00

... exclusivity, the biosimilar industry stands as the sole gainer. A new research study conducted by RNCOS, “Global Biosimilar Market Outlook 2020”, reveals that the market, which was worth US$ 1.89 Billion in 2014, is expected to reach US$ 25.53 Billion by 2020, growing at an impressive CAGR ...

Apr, 2015 110 pages
Therapy Class Overview: Rituximab biosimilar US$ 2,000.00

... /Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which ... the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales ...

Oct, 2013 45 pages
Physician Views: How do Indian oncologists plan to use biosimilar Herceptin? US$ 695.00

... to drive a notable shift in the Indian trastuzumab market, this week's Physician Views poll asks Indian oncologists to provide their initial views on what its availability will ... drug) or across the HER2-positive breast cancer treatment paradigm? How confident they are in using CANMAb given the relative size ...

Jan, 2014
The Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market US$ 3,900.00

... Coming Age of Biosimilars - Regulatory developments and alliance strategies intensify interest in a developing market” is a consultancy-style report focused on the many increasing topics of biosimilars and ... competitive landscape for biosimilars. Scope Introduction, overview and drivers and barriers to the biosimilars market Opportunity avenues and biosimilars defense strategies Competitive ...

May, 2011 58 pages
Biosimilars - The Future Transformation of Product Exclusivity in the Biotechnology Arena US$ 3,900.00

... Overview, history and Biosimilar landscape Biotech patent exclusivity precedence Laws and legislation related to biosimilars Profiles of top biosimilar players Future outlook Key ... most in the near term and from which biosimilar companies Gain insight from our biosimilar industry interviews as key comments and viewpoints ...

Jun, 2009 53 pages
Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin))... US$ 4,650.00

... the biosimilars market by product and application. On the basis of products, the biosimilars market is segmented into recombinant nonglycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant nonglycosylated proteins market is further ... pointers: Market Penetration: Comprehensive information on biosimilar products offered by the top 10 players in the biosimilars market. The report analyzes the biosimilars market by product and application across geographie

Jul, 2015 153 pages
Commercialisation of Biosimilars: strategies for market penetration US$ 595.00

... world in biosimilar sales. Although the European experience differs markedly from the anticipated evolution of biosimilars in the US, there are lessons to be learned. In Commercialisation of Biosimilars: strategies for ... of how to design strategies to influence key opinion leaders Understand why biosimilar acceptance is slower than most new generic drugs Commercialisation of Biosimilars: strategies for market penetration ...

Nov, 2013 124 pages
Generics/Biosimilars Collection US$ 4,595.00

The collection includes the following reports: Charting the Biosimilar and Biobetter Development Pipeline (2013) Biosimilar Defensive Plays - assessing the options Branded Generics: Strategies and Tactics for Winning in Latin America Biosimilars in Emerging Markets (Volume 1 and Volume 2)

Oct, 2013
Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors US$ 265.00

... of proteins and peptides as agonists of the parathyroid hormone (PTH) receptor. In addition, the report lists company-specific R&D pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ...

Oct, 2013 33 pages
Biological and biosimilars drug market in Poland 2013 US$ 2,660.00

... designed to treat a growing variety of conditions and illnesses. Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 ... using profiles of the major Polish manufacturing companies active in this market that include financial condition updates, plans for upcoming additions ...

Aug, 2013 120 pages
Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 US$ 2,635.00

... ten medicines worldwide by revenue. For those therapies, high potential for biosimilar competition exists. Our analysis predicts those competitors of the leading ... the possibilities, helping you stay ahead. Nine ways Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023 helps you To sum up, our ...

Jul, 2013 150 pages
Biosimilar Opportunities in an Evolving Market US$ 1,495.00

... of the company’s development agreement with Actavis. In June 2012, Merck KGaA and Dr Reddy's Laboratories announced a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Pfizer has been openly active in generics and biosimilars for some time. ...

Aug, 2013 113 pages
Biologics and Biosimilars World Markets US$ 3,400.00

... provides insight into the regulatory pathways for branded pharmaceuticals and biologics, patent expirations, business strategies, clinical trials and drug applications. ... examines companies that are actively developing and marketing biologics and biosimilars in the world. Detailed tables and charts with sales ...

Aug, 2013 403 pages
South Korea Biosimilar Market Analysis US$ 800.00

... However, with the aggressive government support, and the increasing focus on biosimilars development, the government aims that the country would occupy a significant share of the global market for biosimilars by 2020. “South Korea Biosimilar Market Analysis” reports gives comprehensive details on following ...

Jan, 2014 110 pages
Biosimilar Defensive Plays - Assessing the options US$ 495.00

... . This insightful report brings you completely up to date with the biosimilar competitive landscape, and gives you the information you need ... .” Warwick Smith, director-general, British Generic Manufacturers Association Biosimilar Defensive Plays - assessing the options is designed to answer your strategic and ...

Jun, 2013 87 pages
PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013 US$ 2,995.00

PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013 Summary GlobalData’s 'PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013', provides strategic analysis of the global biosimilars industry. It discusses ...

May, 2013 152 pages
Biosimilars in Emerging Markets US$ 665.00

... analysis of the trends which are shaping its development. Biosimilars in Emerging Markets is a 2-volume report which provides both a comprehensive overview of the ... over safety and quality. Volume 2 brings together highly-detailed market analysis with contributions from local industry experts whose clear ...

Mar, 2013 226 pages
Therapeutic Class Report Overview - Rituxan Biosimilar US$ 2,000.00

The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roche’s/Biogen Idec’s Rituxan/MabThera (rituximab), Merck ...

Feb, 2013 45 pages
Therapeutic Class Report Overview - Japan Biosimilars US$ 1,000.00

... therapy brings significant burden on patients despite relatively low co-pay in Japan – and this will push individuals and DPC Hospitals to use ... macro forces as compared to generics, a number of companies aim to exploit this – Japan has seen a flood like consolidation and partnering activities in biosimilar ...

Jan, 2013 32 pages
1 2 >
Skip to top